Rate of progression in Parkinson's disease: A 6‐[18F]fluoro‐L‐dopa PET study
Identifieur interne : 001A22 ( Main/Exploration ); précédent : 001A21; suivant : 001A23Rate of progression in Parkinson's disease: A 6‐[18F]fluoro‐L‐dopa PET study
Auteurs : Elina Nurmi [Finlande] ; Hanna M. Ruottinen [Finlande] ; Jörgen Bergman [Finlande] ; Merja Haaparanta [Finlande] ; Olof Solin [Finlande] ; Pirkko Sonninen [Finlande] ; Juha O. Rinne [Finlande]Source :
- Movement Disorders [ 0885-3185 ] ; 2001-07.
English descriptors
Abstract
The aim of this study was to investigate the rate of progression in Parkinson's disease (PD) with 6‐[18F]fluoro‐L‐dopa (FDOPA) positron emission tomography (PET). We investigated 21 patients with PD and eight healthy controls. Ten of the patients were de novo at the time of the first PET scan and antiparkinsonian medication was started thereafter, with a favourable response. A FDOPA PET scan was carried out twice at an approximately 5‐year interval. The regions of interest were drawn on individual magnetic resonance imaging (MRI) images, matched with the PET images. At the first PET scan, in PD patients the mean kiocc (× 10−3 min−1) in the anterior putamen was 5.6 ± 2.7 (mean ± S.D.; 55% of the control mean) and in the posterior putamen 4.5 ± 2.4 (45% of the control mean). The kiocc value for the caudate nucleus was 7.5 ± 2.1 (× 10−3 min−1; 76% of the control mean). The FDOPA uptake declined by the time of the second PET scan and the annual rate of decline was 8.3 ± 6.3% (P < 0.001) of the baseline mean in the anterior putamen and 10.3 ± 4.8% (P < 0.001) in the posterior putamen. In the caudate nucleus, FDOPA uptake decreased by 5.9 ± 5.1% (P < 0.001) of the baseline mean per year. The estimated preclinical period was longest for the posterior putamen being 6.5 years. For the anterior putamen the preclinical period was 4.6 years. In the caudate nucleus, the estimated FDOPA uptake was at normal level at disease onset. In healthy controls, there was no significant decline in FDOPA uptake in any striatal subregion. Our results suggest that the disease process in PD first affects posterior putamen, followed by the anterior putamen and the caudate nucleus, but once started, the absolute rate of decline is the same. In healthy controls, no significant decline in FDOPA was detected. © 2001 Movement Disorder Society.
Url:
DOI: 10.1002/mds.1139
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rate of progression in Parkinson's disease: A 6‐[18F]fluoro‐L‐dopa PET study</title><author><name sortKey="Nurmi, Elina" sort="Nurmi, Elina" uniqKey="Nurmi E" first="Elina" last="Nurmi">Elina Nurmi</name></author><author><name sortKey="Ruottinen, Hanna M" sort="Ruottinen, Hanna M" uniqKey="Ruottinen H" first="Hanna M." last="Ruottinen">Hanna M. Ruottinen</name></author><author><name sortKey="Bergman, Jorgen" sort="Bergman, Jorgen" uniqKey="Bergman J" first="Jörgen" last="Bergman">Jörgen Bergman</name></author><author><name sortKey="Haaparanta, Merja" sort="Haaparanta, Merja" uniqKey="Haaparanta M" first="Merja" last="Haaparanta">Merja Haaparanta</name></author><author><name sortKey="Solin, Olof" sort="Solin, Olof" uniqKey="Solin O" first="Olof" last="Solin">Olof Solin</name></author><author><name sortKey="Sonninen, Pirkko" sort="Sonninen, Pirkko" uniqKey="Sonninen P" first="Pirkko" last="Sonninen">Pirkko Sonninen</name></author><author><name sortKey="Rinne, Juha O" sort="Rinne, Juha O" uniqKey="Rinne J" first="Juha O." last="Rinne">Juha O. Rinne</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:CD92A9CF64114C39DC4DA24600A15F13E81FF7E4</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1002/mds.1139</idno><idno type="url">https://api.istex.fr/document/CD92A9CF64114C39DC4DA24600A15F13E81FF7E4/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001725</idno><idno type="wicri:Area/Main/Curation">001489</idno><idno type="wicri:Area/Main/Exploration">001A22</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Rate of progression in Parkinson's disease: A 6‐[18F]fluoro‐L‐dopa PET study</title><author><name sortKey="Nurmi, Elina" sort="Nurmi, Elina" uniqKey="Nurmi E" first="Elina" last="Nurmi">Elina Nurmi</name><affiliation wicri:level="4"><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Neurology, and Turku PET Centre, University of Turku, Turku</wicri:regionArea><placeName><settlement type="city">Turku</settlement><region type="région" nuts="2">Finlande occidentale</region></placeName><orgName type="university">Université de Turku</orgName></affiliation></author><author><name sortKey="Ruottinen, Hanna M" sort="Ruottinen, Hanna M" uniqKey="Ruottinen H" first="Hanna M." last="Ruottinen">Hanna M. Ruottinen</name><affiliation wicri:level="4"><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Neurology, and Turku PET Centre, University of Turku, Turku</wicri:regionArea><placeName><settlement type="city">Turku</settlement><region type="région" nuts="2">Finlande occidentale</region></placeName><orgName type="university">Université de Turku</orgName></affiliation></author><author><name sortKey="Bergman, Jorgen" sort="Bergman, Jorgen" uniqKey="Bergman J" first="Jörgen" last="Bergman">Jörgen Bergman</name><affiliation wicri:level="3"><country xml:lang="fr">Finlande</country><wicri:regionArea>Radiochemistry Laboratory, Turku PET Centre, Turku</wicri:regionArea><placeName><settlement type="city">Turku</settlement><region type="région" nuts="2">Finlande occidentale</region></placeName></affiliation></author><author><name sortKey="Haaparanta, Merja" sort="Haaparanta, Merja" uniqKey="Haaparanta M" first="Merja" last="Haaparanta">Merja Haaparanta</name><affiliation wicri:level="3"><country xml:lang="fr">Finlande</country><wicri:regionArea>Radiochemistry Laboratory, Turku PET Centre, Turku</wicri:regionArea><placeName><settlement type="city">Turku</settlement><region type="région" nuts="2">Finlande occidentale</region></placeName></affiliation></author><author><name sortKey="Solin, Olof" sort="Solin, Olof" uniqKey="Solin O" first="Olof" last="Solin">Olof Solin</name><affiliation wicri:level="3"><country xml:lang="fr">Finlande</country><wicri:regionArea>Radiochemistry Laboratory, Turku PET Centre, Turku</wicri:regionArea><placeName><settlement type="city">Turku</settlement><region type="région" nuts="2">Finlande occidentale</region></placeName></affiliation></author><author><name sortKey="Sonninen, Pirkko" sort="Sonninen, Pirkko" uniqKey="Sonninen P" first="Pirkko" last="Sonninen">Pirkko Sonninen</name><affiliation wicri:level="4"><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Radiology, University of Turku, Turku</wicri:regionArea><placeName><settlement type="city">Turku</settlement><region type="région" nuts="2">Finlande occidentale</region></placeName><orgName type="university">Université de Turku</orgName></affiliation></author><author><name sortKey="Rinne, Juha O" sort="Rinne, Juha O" uniqKey="Rinne J" first="Juha O." last="Rinne">Juha O. Rinne</name><affiliation wicri:level="4"><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Neurology, and Turku PET Centre, University of Turku, Turku</wicri:regionArea><placeName><settlement type="city">Turku</settlement><region type="région" nuts="2">Finlande occidentale</region></placeName><orgName type="university">Université de Turku</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2001-07">2001-07</date><biblScope unit="volume">16</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="608">608</biblScope><biblScope unit="page" to="615">615</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">CD92A9CF64114C39DC4DA24600A15F13E81FF7E4</idno><idno type="DOI">10.1002/mds.1139</idno><idno type="ArticleID">MDS1139</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>PET</term><term>Parkinson's disease</term><term>fluorodopa</term><term>positron emission tomography</term><term>progression</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aim of this study was to investigate the rate of progression in Parkinson's disease (PD) with 6‐[18F]fluoro‐L‐dopa (FDOPA) positron emission tomography (PET). We investigated 21 patients with PD and eight healthy controls. Ten of the patients were de novo at the time of the first PET scan and antiparkinsonian medication was started thereafter, with a favourable response. A FDOPA PET scan was carried out twice at an approximately 5‐year interval. The regions of interest were drawn on individual magnetic resonance imaging (MRI) images, matched with the PET images. At the first PET scan, in PD patients the mean kiocc (× 10−3 min−1) in the anterior putamen was 5.6 ± 2.7 (mean ± S.D.; 55% of the control mean) and in the posterior putamen 4.5 ± 2.4 (45% of the control mean). The kiocc value for the caudate nucleus was 7.5 ± 2.1 (× 10−3 min−1; 76% of the control mean). The FDOPA uptake declined by the time of the second PET scan and the annual rate of decline was 8.3 ± 6.3% (P < 0.001) of the baseline mean in the anterior putamen and 10.3 ± 4.8% (P < 0.001) in the posterior putamen. In the caudate nucleus, FDOPA uptake decreased by 5.9 ± 5.1% (P < 0.001) of the baseline mean per year. The estimated preclinical period was longest for the posterior putamen being 6.5 years. For the anterior putamen the preclinical period was 4.6 years. In the caudate nucleus, the estimated FDOPA uptake was at normal level at disease onset. In healthy controls, there was no significant decline in FDOPA uptake in any striatal subregion. Our results suggest that the disease process in PD first affects posterior putamen, followed by the anterior putamen and the caudate nucleus, but once started, the absolute rate of decline is the same. In healthy controls, no significant decline in FDOPA was detected. © 2001 Movement Disorder Society.</div></front></TEI><affiliations><list><country><li>Finlande</li></country><region><li>Finlande occidentale</li></region><settlement><li>Turku</li></settlement><orgName><li>Université de Turku</li></orgName></list><tree><country name="Finlande"><region name="Finlande occidentale"><name sortKey="Nurmi, Elina" sort="Nurmi, Elina" uniqKey="Nurmi E" first="Elina" last="Nurmi">Elina Nurmi</name></region><name sortKey="Bergman, Jorgen" sort="Bergman, Jorgen" uniqKey="Bergman J" first="Jörgen" last="Bergman">Jörgen Bergman</name><name sortKey="Haaparanta, Merja" sort="Haaparanta, Merja" uniqKey="Haaparanta M" first="Merja" last="Haaparanta">Merja Haaparanta</name><name sortKey="Rinne, Juha O" sort="Rinne, Juha O" uniqKey="Rinne J" first="Juha O." last="Rinne">Juha O. Rinne</name><name sortKey="Ruottinen, Hanna M" sort="Ruottinen, Hanna M" uniqKey="Ruottinen H" first="Hanna M." last="Ruottinen">Hanna M. Ruottinen</name><name sortKey="Solin, Olof" sort="Solin, Olof" uniqKey="Solin O" first="Olof" last="Solin">Olof Solin</name><name sortKey="Sonninen, Pirkko" sort="Sonninen, Pirkko" uniqKey="Sonninen P" first="Pirkko" last="Sonninen">Pirkko Sonninen</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A22 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001A22 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:CD92A9CF64114C39DC4DA24600A15F13E81FF7E4
|texte= Rate of progression in Parkinson's disease: A 6‐[18F]fluoro‐L‐dopa PET study
}}
| This area was generated with Dilib version V0.6.23. |  |